Polysorbate 80 vs Recombinant Bovine Growth Hormone: which is worse?

What is Polysorbate 80?

Polysorbate 80 (Tween 80) is a synthetic nonionic surfactant and emulsifier derived from sorbitol and oleic acid (from vegetable oils) through ethoxylation. It is widely used in food to keep water-based and oil-based ingredients uniformly mixed. Chemical formula: polyoxyethylene (20) sorbitan monooleate.

What is Recombinant Bovine Growth Hormone?

Recombinant bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST), is a synthetically produced version of the naturally occurring cattle growth hormone, manufactured using genetically engineered E. coli bacteria. Injected into dairy cows, it increases milk production by 10-15%. It was FDA-approved in 1993 under the brand name Posilac (originally Monsanto, later Elanco).

Documented risks

Polysorbate 80: Emerging research has raised concerns about polysorbate 80's effects on the gut. A landmark 2015 study in Nature (Chassaing et al.) found that dietary polysorbate 80 and polysorbate 60 at concentrations approaching food use levels promoted colitis and metabolic syndrome in genetically susceptible mice by disrupting the intestinal mucus layer and altering gut microbiome composition. The emulsifiers thinned the protective mucus layer, allowing bacteria to come into closer contact with gut epithelial cells and triggering inflammation. This study was a seminal contribution to gut health research, though it was conducted in mice and requires confirmation in humans. A 2020 follow-up study found that dietary emulsifiers including polysorbate 80 promoted gut inflammation and altered gut microbiome in human participants with Crohn's disease. People with inflammatory bowel disease may be most vulnerable to polysorbate 80's potential gut effects.

Recombinant Bovine Growth Hormone: The central human health concern is that rBGH treatment significantly elevates insulin-like growth factor 1 (IGF-1) levels in treated cows' milk. IGF-1 is a naturally occurring growth hormone that promotes cell growth and division. Multiple epidemiological studies have associated elevated blood IGF-1 levels with increased cancer risk in humans. A 1998 study in The Lancet (Hankinson et al.) found that women with the highest IGF-1 blood levels had approximately 7 times the breast cancer risk compared to those with the lowest levels. A 2004 meta-analysis in JNCI (the Journal of the National Cancer Institute) confirmed significant associations between high IGF-1 levels and breast, prostate, and colorectal cancer risk. The mechanistic question is whether consuming rBGH-treated milk raises blood IGF-1 levels in humans. The FDA and WHO/FAO Codex Alimentarius concluded that IGF-1 in milk is a protein largely digested in the GI tract before absorption. Canadian regulatory researchers challenged this, arguing that pasteurization reduces proteases that would otherwise break down IGF-1, potentially allowing more intact IGF-1 to survive digestion. The Codex Alimentarius Commission made history in 1999 by declining to endorse rBST safety maximum residue limits — a split vote (33 in favor of the MRL, 29 against, with abstentions) demonstrating fundamental international disagreement. This is one of very few cases where Codex failed to establish a safety standard. Animal welfare is a second major concern: Health Canada's comprehensive 1999 review found that rBGH-treated cows had 25% higher rates of clinical mastitis, 50% higher lameness risk, increased reproductive problems, and shortened productive lifespans, requiring substantially more antibiotic treatment — an antibiotic resistance concern. Canada rejected rBGH approval in 1999 after its scientific review; the EU banned it in 1999.